Strepsils Intensive Sugar-Free Lozenges 8.75 mg Orange Flavor No. 16

Instructions for Strepsils Intensive sugar-free lozenges 8.75 mg with orange flavor No. 16

Composition

active ingredient: flurbiprofen; 1 lollipop contains 8.75 mg of flurbiprofen; excipients: macrogol 300 (polyethylene glycol 300), potassium hydroxide, orange flavoring PHL-010300, levomenthol, acesulfame K, liquid maltitol *, isomaltitol (E 953).

Contraindication

Hypersensitivity to flurbiprofen, acetylsalicylic acid, other NSAIDs or to any of the excipients of the drug. Allergic diseases in the past (e.g. bronchospasm, rhinitis, urticaria) after taking acetylsalicylic acid or other NSAIDs. Last trimester of pregnancy. Children under 12 years of age. Gastric or intestinal ulcer, gastrointestinal bleeding, severe colitis, bleeding or blood disorders associated with previous NSAID therapy. Severe heart failure, severe renal failure or severe hepatic failure.

Adverse reactions

Nervous system disorders: common: headache, dizziness; uncommon: drowsiness.

Respiratory, thoracic and mediastinal disorders: Common: throat irritation; uncommon: exacerbation of bronchial asthma and bronchospasm, dyspnoea, oropharyngeal blisters, pharyngeal hypoesthesia.

Gastrointestinal: very common (13.6%): oral discomfort (feeling of warmth, burning or tingling in the mouth); common: nausea, diarrhea, oral ulcers, dry mouth, oropharyngeal pain; uncommon: dyspepsia, vomiting, flatulence, abdominal distension, abdominal pain, constipation, glossodynia, dysgeusia, oral dysesthesia.

Skin and subcutaneous tissue disorders: uncommon: exanthema, various skin rashes, itching.

General disorders and local reactions: uncommon: fever, pain.

Psychiatric disorders: uncommon: insomnia.

Method of application

The lowest effective dose is used for the shortest period necessary to relieve symptoms.

Lollipops are not recommended for use for more than 3 days without consulting a doctor.

Adults and children over 12 years of age: take 1 lozenge every 3 to 6 hours as needed; dissolve slowly in the mouth. The maximum daily dose is 5 lozenges.

It is not recommended to use the drug for more than 3 days without consulting a doctor.

When dissolving, the lollipop, like all lozenges, should be moved throughout the oral cavity to prevent irritation of the mucous membrane at the site of resorption. until it dissolves.

Treatment should be discontinued if irritation of the oral mucosa develops.

Use during pregnancy or breastfeeding

The following data only apply to systemically acting flurbiprofen. There are no data on topical flurbiprofen.

First and second trimester: Animal studies have shown no evidence of teratogenic effects. However, there are no controlled clinical studies in pregnant women.

Therefore, it is not recommended to use the drug during the first and second trimester of pregnancy.

Third trimester: Inhibition of prostaglandin synthesis may lead to premature closure of the ductus arteriosus during the last trimester of pregnancy and may affect labour (inhibition of uterine contractions). Flurbiprofen is therefore contraindicated during the third trimester of pregnancy.

Flurbiprofen passes into breast milk in very low concentrations. Flurbiprofen is not recommended for use in women who are breastfeeding.

Children

Do not use in children under 12 years of age,

Ability to influence reaction speed when driving vehicles or other mechanisms

There are no data on the effect on the reaction speed when driving vehicles or other mechanisms.

Overdose

There is no specific antidote to flurbiprofen.

Symptoms. In most patients, the use of clinically significant amounts of HP33 caused only nausea, vomiting, epigastric pain, or less commonly diarrhea. Tinnitus, headache, and gastrointestinal bleeding may also occur. In more severe poisoning, toxic lesions of the central nervous system in the form of drowsiness, sometimes - agitation, visual disturbances, disorientation, or coma are possible. Convulsions may rarely occur.

In severe poisoning with NPZ3, metabolic acylose and an increase in prothrombin time may occur, probably due to interaction with blood clotting factors circulating in the bloodstream. Acute renal failure and liver damage may occur. In patients with bronchial asthma, exacerbation of asthma is possible.

Treatment. Treatment should be symptomatic and supportive. It is important to ensure a patent airway. Cardiac function and vital signs should be monitored to normalize the patient's condition. Oral administration of activated charcoal is recommended within 1 hour of a potentially toxic dose. In case of frequent or prolonged muscle spasms, treatment should be carried out with intravenous diazepam or lorazepam. In case of bronchial asthma, bronchodilators should be used.

Storage conditions

Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.